Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn

Table of Contents

February 01, 1996; Volume 276,Issue 2
  • You have access
    Inhibition of cerebral neurogenic vasodilation by L-glutamine and nitric oxide synthase inhibitors and its reversal by L-citrulline.
    T J Lee, S Sarwinski, T Ishine, C C Lai and F Y Chen
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 353-358;
  • You have access
    I2-imidazoline binding sites: relationship with different monoamine oxidase domains and identification of histidine residues mediating ligand binding regulation by H+1.
    I Limon-Boulez, F Tesson, C Gargalidis-Moudanos and A Parini
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 359-364;
  • You have access
    Activation of cyclic AMP-dependent protein kinase reverses tolerance of a nucleoside transporter to ethanol.
    I R Coe, D P Dohrman, A Constantinescu, I Diamond and A S Gordon
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 365-369;
  • You have access
    Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole.
    L L von Moltke, D J Greenblatt, J S Harmatz, S X Duan, L M Harrel, M M Cotreau-Bibbo, G A Pritchard, C E Wright and R I Shader
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 370-379;
  • You have access
    BMS-180448, a novel glyburide-reversible cardioprotective agent, enhances postischemic recovery of contractile function in dogs.
    G J Grover, C S Parham, D B Whigan and J G Mitroka
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 380-387;
  • You have access
    Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist/5-HT2A/2C antagonist anxiolytics. I. Antipunishment effects in the pigeon.
    M S Kleven and W Koek
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 388-397;
  • You have access
    The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist.
    C Zocchi, E Ongini, A Conti, A Monopoli, A Negretti, P G Baraldi and S Dionisotti
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 398-404;
  • You have access
    The quaternary transformation products of N-(3-chloropropyl)-4-piperidinyl diphenylacetate and N-(2-chloroethyl)-4-piperidinyl diphenylacetate (4-DAMP mustard) have differential affinity for subtypes of the muscarinic receptor.
    F J Ehlert, H S Oliff and M T Griffin
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 405-410;
  • You have access
    Role of imidazoline receptors in the cardiovascular actions of moxonidine, rilmenidine and clonidine in conscious rabbits.
    C K Chan, F Sannajust and G A Head
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 411-420;
  • You have access
    Oral biological activities of spontaneous nitric oxide releasers are accounted for by their nitric oxide-releasing rates and oral absorption manners.
    Y Kita, Y Hirasawa, S Fukuyama, K Ohkubo, Y Kato, H Takamatsu, M Ohno, S Nishino, M Kato and J Seki
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 421-425;
  • You have access
    Effects of somatostatin and related peptides on the membrane potential and input resistance of rat ventral subicular neurons, in vitro.
    J R Greene and A Mason
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 426-432;
  • You have access
    Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154.
    Y Abe, R Ishisu, K Onishi, K Sekioka, A Narimatsu and T Nakano
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 433-439;
  • You have access
    Relative analgesic potency of mu, delta and kappa opioids after spinal administration in amphibians.
    C W Stevens
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 440-448;
  • You have access
    Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans.
    T Eissenberg, M K Greenwald, R E Johnson, I A Liebson, G E Bigelow and M L Stitzer
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 449-459;
  • You have access
    The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice.
    K Yamada, Y Noda, T Hasegawa, Y Komori, T Nikai, H Sugihara and T Nabeshima
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 460-466;
  • You have access
    Selective inhibition by a class III antiarrhythmic agent, E-4031, of the negative chronotropic response to parasympathetic stimulation in anesthetized dogs.
    H Imamura, Y Furukawa, H Nakano, M Kasama, Y Hoyano and S Chiba
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 467-472;
  • You have access
    Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
    T J Opgenorth, A L Adler, S V Calzadilla, W J Chiou, B D Dayton, D B Dixon, L J Gehrke, L Hernandez, S R Magnuson, K C Marsh, E I Novosad, T W Von Geldern, J L Wessale, M Winn and J R Wu-Wong
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 473-481;
  • You have access
    Nicotine-induced inhibition in medial septum involves activation of presynaptic nicotinic cholinergic receptors on gamma-aminobutyric acid-containing neurons.
    X Yang, H E Criswell and G R Breese
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 482-489;
  • You have access
    Characterization of 8-(N-methylisopropyl)amino-N6-(5'-endohydroxy- endonorbornyl)-9-methyladenine (WRC-0571), a highly potent and selective, non-xanthine antagonist of A1 adenosine receptors.
    P L Martin, R J Wysocki, R J Barrett, J M May and J Linden
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 490-499;
  • You have access
    Characterization of the antinociceptive properties of cimetidine and a structural analog.
    B Y Li, J W Nalwalk, L A Barker, P Cumming, M E Parsons and L B Hough
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 500-508;
  • You have access
    Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.
    A I Sacaan, F Menzaghi, J L Dunlop, L D Correa, K T Whelan and G K Lloyd
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 509-515;
  • You have access
    Modulation of seizure activity in mice by metabotropic glutamate receptor ligands.
    N O Dalby and C Thomsen
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 516-522;
  • You have access
    Discriminative stimulus effects of nalbuphine in rhesus monkeys.
    L R Gerak and C P France
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 523-531;
  • You have access
    Differential genetic mediation of sensitivity to morphine in genetic models of opiate antinociception: influence of nociceptive assay.
    J S Mogil, B Kest, B Sadowski and J K Belknap
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 532-544;
  • You have access
    kappa-Opioid receptor agonists prevent sensitization to the conditioned rewarding effects of cocaine.
    T S Shippenberg, A LeFevour and C Heidbreder
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 545-554;
  • You have access
    Effects of lipid A on calcium homeostasis in renal proximal tubules.
    J W Proksch, L A Traylor and P R Mayeux
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 555-560;
  • You have access
    Mechanisms for the hepatic uptake and biliary excretion of tributylmethylammonium: studies with rat liver plasma membrane vesicles.
    R H Moseley, H Smit, B G Van Solkema, W Wang and D K Meijer
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 561-567;
  • You have access
    Cocaine concentration-effect relationship in the presence and absence of lidocaine: evidence of competitive binding between cocaine and lidocaine.
    D Liu, R J Hariman and J L Bauman
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 568-577;
  • You have access
    Glucocorticoid interactions with ethanol effects on synaptic plasma membranes: influence on [125I]calmodulin binding.
    P Y Sze
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 578-584;
  • You have access
    Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
    A H Lichtman, S A Cook and B R Martin
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 585-593;
  • You have access
    A three-lever operant procedure differentiates the stimulus effects of R(-)-MDA from S(+)-MDA.
    R Young and R A Glennon
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 594-601;
  • You have access
    Effect of lipid-free total parenteral nutrition on hepatic drug conjugation in rats.
    R B Raftogianis, M R Franklin and R E Galinsky
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 602-608;
  • You have access
    Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    E H Ohlstein, P Nambi, A Lago, D W Hay, G Beck, K L Fong, E P Eddy, P Smith, H Ellens and J D Elliott
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 609-615;
  • You have access
    Cooperative contributions of cholinergic and NMDA receptors in the presynaptic control of dopamine release from synaptosomes of the rat striatum.
    A Chéramy, G Godeheu, M L'Hirondel and J Glowinski
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 616-625;
  • You have access
    Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats.
    K Fecho, K A Maslonek, L A Dykstra and D T Lysle
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 626-636;
  • You have access
    Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
    A Bril, B Gout, M Bonhomme, L Landais, J F Faivre, P Linee, R H Poyser and R R Ruffolo
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 637-646;
  • You have access
    Endothelin-induced nociception in mice: mediation by ETA and ETB receptors.
    R B Raffa, J J Schupsky and H I Jacoby
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 647-651;
  • You have access
    Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism.
    M Y Farhat, S Abi-Younes, B Dingaan, R Vargas and P W Ramwell
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 652-657;
  • You have access
    Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.
    B J Ring, J Catlow, T J Lindsay, T Gillespie, L K Roskos, B J Cerimele, S P Swanson, M A Hamman and S A Wrighton
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 658-666;
  • You have access
    Low level hyperbaric antagonism of diazepam's locomotor depressant and anticonvulsant properties in mice.
    D L Davies, M Bejanian, E S Parker, J Mørland, M B Bolger, R D Brinton and R L Alkana
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 667-675;
  • You have access
    Saturable disposition of taurine in the rat cerebrospinal fluid.
    S J Chung, V K Ramanathan, C M Brett and K M Giacomini
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 676-682;
  • You have access
    Urine acidification affects the activity of the organic base transporter in a nonstereoselective manner.
    M R Ujhelyi, M B Bottorff, M Schur, K Roll, H Zhang, J Stewart and M L Markel
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 683-689;
  • You have access
    A G protein, not cyclic AMP, mediates effects of VIP on the inwardly rectifying K+ channels in endothelial cells.
    E A Pasyk, S Cipris and E E Daniel
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 690-696;
  • You have access
    Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration.
    G Piñeyro and P Blier
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 697-707;
  • You have access
    Determinants of in vivo activity of neutral endopeptidase 3.4.24.11 and angiotensin converting enzyme inhibitors.
    A A Seymour, M M Asaad, B E Abboa-Offei, P L Smith, W L Rogers and C R Dorso
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 708-713;
  • You have access
    Somatostatin inhibits bombesin-stimulated Gi-protein via its own receptor in rabbit colonic smooth muscle cells.
    K N Bitar, S Kothary and P C Kothary
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 714-719;
  • You have access
    Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.
    D B Wainscott, V L Lucaites, J D Kursar, M Baez and D L Nelson
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 720-727;
  • You have access
    Effects of metabolites of leukotriene B4 on human neutrophil migration and cytosolic calcium levels.
    W S Powell, J Rokach, S P Khanapure, S Manna, M Hashefi, S Gravel, R J Macleod, J R Falck and R K Bhatt
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 728-736;
  • You have access
    Noncompetitive NMDA channel blockade during waking intensely stimulates NREM delta.
    I G Campbell and I Feinberg
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 737-742;
  • You have access
    Dexamethasone selective inhibition of acute opioid physical dependence in isolated tissues.
    A Capasso, A Di Giannuario, A Loizzo, S Pieretti, S Sagratella and L Sorrentino
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 743-751;
  • You have access
    Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic-3',5'-guanosine monophosphate-stimulated phosphodiesterase to reverse hypoxic pulmonary vasoconstriction in the perfused rat lung.
    J Haynes, D W Killilea, P D Peterson and W J Thompson
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 752-757;
  • You have access
    Three-day exposure to low-dose ethanol alters guanine nucleotide binding protein expression in the developing rat hippocampus.
    M I Davis-Cox, T L Fletcher, J N Turner, D Szarowski and W Shain
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 758-764;
  • You have access
    Arbutin: mechanism of its depigmenting action in human melanocyte culture.
    K Maeda and M Fukuda
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 765-769;
  • You have access
    Galactose-modified streptavidin-GC4 antifibrin monoclonal antibody conjugates: application for two-step thrombus/embolus imaging.
    S F Rosebrough and M Hashmi
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 770-775;
  • You have access
    Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation.
    Y Daaka, H Friedman and T W Klein
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 776-783;
  • You have access
    Differential coupling of rat D2 dopamine receptor isoforms expressed in Spodoptera frugiperda insect cells.
    V A Boundy, L Lu and P B Molinoff
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 784-794;
  • You have access
    Effects of single and short-term administration of clonidine on hypothalamic-pituitary somatotropic function of the adult male rat: an in situ hybridization study.
    V De Gennaro Colonna, M Zoli, B P Settembrini, S Ciceri, A De Marco, S G Cella, L F Agnati and E E Muller
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 795-800;
  • You have access
    Differential contribution of descending controls to the antinociceptive actions of kappa and mu opioids: an analysis of formalin-evoked C-fos expression.
    K R Gogas, J D Levine and A I Basbaum
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 801-809;
  • You have access
    Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.
    C D Manning, M M McLaughlin, G P Livi, L B Cieslinski, T J Torphy and M S Barnette
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 810-818;
  • You have access
    Pharmacological and immunological characterization of N-methyl-D-aspartate receptors in human NT2-N neurons.
    M Munir, L Lu, Y H Wang, J Luo, B B Wolfe and P McGonigle
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 819-828;
  • You have access
    Homologous desensitization of thromboxane A2 receptor in 1321N1 human astrocytoma cells.
    K Sakai, N Nakahata, H Ono, T Yamamoto and Y Ohizumi
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 829-836;
  • You have access
    Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line.
    H Ali, O H Choi, P F Fraundorfer, K Yamada, H M Gonzaga and M A Beaven
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 837-845;
  • You have access
    Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations.
    K E Sabol, R Lew, J B Richards, G L Vosmer and L S Seiden
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 846-854;
  • You have access
    Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies.
    R Lew, K E Sabol, C Chou, G L Vosmer, J Richards and L S Seiden
    Journal of Pharmacology and Experimental Therapeutics February 1996, 276 (2) 855-865;
Back to top
PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 276, Issue 2
1 Feb 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Read
Loading
  • KBP-042 as Adjunct Therapy to Metformin
  • SARS-CoV-2 Drug Discovery
  • Nose-to-Brain Delivery
  • Interaction between Bupropion and MDMA
  • Smoking Could Worsen COVID-19 Outcome
More...
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics